Larvol Delta - Inhibikase-Therapeutics-Announces-Interim-Threemonth-Results-from-Chronic-Toxicology-Studies-of-its-Oral-cAbl-Kinase-Inhibitor-IkT148009-in-Development-for-Treatment-of-Parkinson39s-Disease

IkT-148009 - Inhibikase, Clintrex

https://www.prnewswire.com/news-releases/inhibikase-therapeutics-announces-interim-three-month-results-from-chronic-toxicology-studies-of-its-oral-c-abl-kinase-inhibitor-ikt-148009-in-development-for-treatment-of-parkinsons-disease-301391388.html

Oct 4, 2021

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next